Retinal Blood Flow as a Predictor of Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Central Retinal Vein Occlusion

Abstract

Introduction: To investigate the relationship between retinal blood flow and the presence or absence of macular edema (ME) recurrence after intravitreal ranibizumab injection (IRI) in patients with central retinal vein occlusion (CRVO). Methods: We reviewed the medical records of 16 eyes with ME associated with CRVO. All eyes had received pro re nata IRI. Repeat IRI was performed if the central macular thickness was ≥300 μm. At 12 months, patients without additional IRI in the past 6 months were assigned to the resolved group, and those with additional IRI, to the recurrence group. We used laser speckle flowgraphy (LSFG) to measure the mean blur rate (MBR) of the optic disc before and after IRI. Results: Ten of the 16 eyes were assigned to the resolved group, and the other 6 eyes to the recurrence group. At several visits in the 12 months after IRI, MBR was significantly higher in the resolved group than in the recurrence group. Percent change of MBR (%ΔMBR) from baseline was significantly higher in the resolved group than in the recurrence group at 1 month (initial %ΔMBR) and 11 and 12 months. Multivariate stepwise analysis showed that the initial %ΔMBR was significantly and negatively correlated with the number of IRIs. Discussion/Conclusion: These findings suggest that determining %ΔMBR in LSFG may be a useful way to determine the likelihood of ME recurrence in CRVO patients.